Collectively, these studies demonstrate that all seven types of CD19 CAR‐NK cells mediate enhanced anti‐tumour activity, particularly when CAR constructs contain CD8 TMD and CD3ζ SD or are combined with OX40 CD. Here, CD8A is linked to neoplasm.